Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in BMC Cancer

Retrieve available abstracts of 66 articles:
HTML format
Text format



Single Articles


    June 2017
  1. YANG J, Zhou Y, Ng SK, Huang KC, et al
    Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
    BMC Cancer. 2017;17:422.
    PubMed     Text format     Abstract available


    May 2017
  2. SCHULER-TOPRAK S, Moehle C, Skrzypczak M, Ortmann O, et al
    Effect of estrogen receptor beta agonists on proliferation and gene expression of ovarian cancer cells.
    BMC Cancer. 2017;17:319.
    PubMed     Text format     Abstract available


    April 2017
  3. LIU Y, Chen S, Zheng C, Ding M, et al
    The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer.
    BMC Cancer. 2017;17:285.
    PubMed     Text format     Abstract available


    February 2017
  4. GANSMO LB, Bjornslett M, Halle MK, Salvesen HB, et al
    MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk.
    BMC Cancer. 2017;17:97.
    PubMed     Text format     Abstract available


    January 2017
  5. MIYAMOTO S, Yotsumoto F, Ueda T, Fukami T, et al
    BK-UM in patients with recurrent ovarian cancer or peritoneal cancer: a first-in-human phase-I study.
    BMC Cancer. 2017;17:89.
    PubMed     Text format     Abstract available


  6. VALTCHEVA N, Lang FM, Noske A, Samartzis EP, et al
    Tracking the origin of simultaneous endometrial and ovarian cancer by next-generation sequencing - a case report.
    BMC Cancer. 2017;17:66.
    PubMed     Text format     Abstract available


  7. AYYAGARI VN, Hsieh TJ, Diaz-Sylvester PL, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines.
    BMC Cancer. 2017;17:49.
    PubMed     Text format     Abstract available


  8. BRANDT S, Samartzis EP, Zimmermann AK, Fink D, et al
    Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer.
    BMC Cancer. 2017;17:44.
    PubMed     Text format     Abstract available


  9. TEMPFER CB, Hartmann F, Hilal Z, Rezniczek GA, et al
    Intraperitoneal cisplatin and doxorubicin as maintenance chemotherapy for unresectable ovarian cancer: a case report.
    BMC Cancer. 2017;17:26.
    PubMed     Text format     Abstract available


    December 2016
  10. MAISTRO S, Teixeira N, Encinas G, Katayama ML, et al
    Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    BMC Cancer. 2016;16:934.
    PubMed     Text format     Abstract available


    November 2016
  11. NAKAMURA H, Nagasaka K, Kawana K, Taguchi A, et al
    Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.
    BMC Cancer. 2016;16:897.
    PubMed     Text format     Abstract available


  12. YU X, Zhang Y, Chen H
    LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.
    BMC Cancer. 2016;16:846.
    PubMed     Text format     Abstract available


    October 2016
  13. YE H, Liu X, Sun J, Zhu S, et al
    Enhanced therapeutic efficacy of LHRHa-targeted brucea javanica oil liposomes for ovarian cancer.
    BMC Cancer. 2016;16:831.
    PubMed     Text format     Abstract available


  14. ORNELAS A, McCullough CR, Lu Z, Zacharias NM, et al
    Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models.
    BMC Cancer. 2016;16:824.
    PubMed     Text format     Abstract available


    February 2016
  15. NARENDRULA R, Mispel-Beyer K, Guo B, Parissenti AM, et al
    RNA disruption is associated with response to multiple classes of chemotherapy drugs in tumor cell lines.
    BMC Cancer. 2016;16:146.
    PubMed     Text format     Abstract available


    January 2016
  16. FENG Z, Wen H, Bi R, Duan Y, et al
    Thrombocytosis and hyperfibrinogenemia are predictive factors of clinical outcomes in high-grade serous ovarian cancer patients.
    BMC Cancer. 2016;16:43.
    PubMed     Text format     Abstract available


  17. SCHMID G, Notaro S, Reimer D, Abdel-Azim S, et al
    Expression and promotor hypermethylation of miR-34a in the various histological subtypes of ovarian cancer.
    BMC Cancer. 2016;16:102.
    PubMed     Text format     Abstract available


  18. WU GJ, Zeng GF
    METCAM/MUC18 is a novel tumor and metastasis suppressor for the human ovarian cancer SKOV3 cells.
    BMC Cancer. 2016;16:136.
    PubMed     Text format     Abstract available


  19. KOUSSOUNADIS A, Langdon SP, Um I, Kay C, et al
    Dynamic modulation of phosphoprotein expression in ovarian cancer xenograft models.
    BMC Cancer. 2016;16:205.
    PubMed     Text format     Abstract available


  20. HIJAZ M, Das S, Mert I, Gupta A, et al
    Folic acid tagged nanoceria as a novel therapeutic agent in ovarian cancer.
    BMC Cancer. 2016;16:220.
    PubMed     Text format     Abstract available


  21. ZHOU J, Zhao M, Tang Y, Wang J, et al
    The milk-derived fusion peptide, ACFP, suppresses the growth of primary human ovarian cancer cells by regulating apoptotic gene expression and signaling pathways.
    BMC Cancer. 2016;16:246.
    PubMed     Text format     Abstract available


  22. STAUDIGL C, Pfeiler G, Hrauda K, Renz R, et al
    Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect".
    BMC Cancer. 2016;16:436.
    PubMed     Text format     Abstract available


  23. SAMARDZIJA C, Luwor RB, Quinn MA, Kannourakis G, et al
    Coalition of Oct4A and beta1 integrins in facilitating metastasis in ovarian cancer.
    BMC Cancer. 2016;16:432.
    PubMed     Text format     Abstract available


  24. XIAO X, Yang G, Bai P, Gui S, et al
    Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathway.
    BMC Cancer. 2016;16:582.
    PubMed     Text format     Abstract available


  25. COZZI GD, Samuel JM, Fromal JT, Keene S, et al
    Thresholds and timing of pre-operative thrombocytosis and ovarian cancer survival: analysis of laboratory measures from electronic medical records.
    BMC Cancer. 2016;16:612.
    PubMed     Text format     Abstract available


  26. KIM MK, Caplen N, Chakka S, Hernandez L, et al
    Identification of therapeutic targets applicable to clinical strategies in ovarian cancer.
    BMC Cancer. 2016;16:678.
    PubMed     Text format     Abstract available


  27. BLOK F, Roes EM, van Leenders GJ, van Beekhuizen HJ, et al
    The lack of clinical value of peritoneal washing cytology in high risk patients undergoing risk-reducing salpingo-oophorectomy: a retrospective study and review.
    BMC Cancer. 2016;16:18.
    PubMed     Text format     Abstract available


  28. PARK B, Park S, Shin HR, Shin A, et al
    Population attributable risks of modifiable reproductive factors for breast and ovarian cancers in Korea.
    BMC Cancer. 2016;16:5.
    PubMed     Text format     Abstract available


  29. LI X, Shen B, Chen Q, Zhang X, et al
    Antitumor effects of cecropin B-LHRH' on drug-resistant ovarian and endometrial cancer cells.
    BMC Cancer. 2016;16:251.
    PubMed     Text format     Abstract available


  30. CHANG YH, Li WH, Chang Y, Peng CW, et al
    Front-line intraperitoneal versus intravenous chemotherapy in stage III-IV epithelial ovarian, tubal, and peritoneal cancer with minimal residual disease: a competing risk analysis.
    BMC Cancer. 2016;16:235.
    PubMed     Text format     Abstract available


    May 2015
  31. MACKENZIE R, Kommoss S, Winterhoff BJ, Kipp BR, et al
    Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    BMC Cancer. 2015;15:415.
    PubMed     Text format     Abstract available


    April 2015
  32. QIAN Q, You Y, Yang J, Cao D, et al
    Management and prognosis of patients with ovarian sex cord tumor with annular tubules: a retrospective study.
    BMC Cancer. 2015;15:270.
    PubMed     Text format     Abstract available


  33. CABURET S, Anttonen M, Todeschini AL, Unkila-Kallio L, et al
    Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes.
    BMC Cancer. 2015;15:251.
    PubMed     Text format     Abstract available


    March 2015
  34. JOZWIK M, Okungbowa OE, Lipska A, Jozwik M, et al
    Surface antigen expression on peripheral blood monocytes in women with gynecologic malignancies.
    BMC Cancer. 2015;15:129.
    PubMed     Text format     Abstract available


    January 2015
  35. PYLVAS-EEROLA M, Karihtala P, Puistola U
    Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
    BMC Cancer. 2015;15:493.
    PubMed     Text format     Abstract available


  36. MEYS EM, Rutten IJ, Kruitwagen RF, Slangen BF, et al
    Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlan
    BMC Cancer. 2015;15:482.
    PubMed     Text format     Abstract available


  37. MCEVOY LM, O'Toole SA, Spillane CD, Martin CM, et al
    Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    BMC Cancer. 2015;15:547.
    PubMed     Text format     Abstract available


  38. REN Y, Jiang R, Yin S, You C, et al
    Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.
    BMC Cancer. 2015;15:583.
    PubMed     Text format     Abstract available


  39. COOKE NM, Spillane CD, Sheils O, O'Leary J, et al
    Aspirin and P2Y12 inhibition attenuate platelet-induced ovarian cancer cell invasion.
    BMC Cancer. 2015;15:627.
    PubMed     Text format     Abstract available


  40. SUN F, Ding W, He JH, Wang XJ, et al
    Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    BMC Cancer. 2015;15:746.
    PubMed     Text format     Abstract available


  41. REFKY B, Kotb S, Fady T, Marwan A, et al
    Impact of liver cirrhosis due to chronic hepatitis C viral infection on the outcome of ovarian cancer: a prospective study.
    BMC Cancer. 2015;15:754.
    PubMed     Text format     Abstract available


  42. JATOI A, Foster NR, Kalli KR, Vierkant RA, et al
    Prior oral contraceptive use in ovarian cancer patients: assessing associations with overall and progression-free survival.
    BMC Cancer. 2015;15:711.
    PubMed     Text format     Abstract available


  43. ARSENIC R, Braicu EI, Letsch A, Dietel M, et al
    Cancer-testis antigen cyclin A1 is broadly expressed in ovarian cancer and is associated with prolonged time to tumor progression after platinum-based therapy.
    BMC Cancer. 2015;15:784.
    PubMed     Text format     Abstract available


  44. ZHOU C, Kang J, Wang X, Wei W, et al
    Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models.
    BMC Cancer. 2015;15:889.
    PubMed     Text format     Abstract available


  45. FOURCADIER E, Tretarre B, Gras-Aygon C, Ecarnot F, et al
    Under-treatment of elderly patients with ovarian cancer: a population based study.
    BMC Cancer. 2015;15:937.
    PubMed     Text format     Abstract available


  46. YAO X, Dong Z, Zhang Q, Wang Q, et al
    Epithelial ovarian cancer stem-like cells expressing alpha-gal epitopes increase the immunogenicity of tumor associated antigens.
    BMC Cancer. 2015;15:956.
    PubMed     Text format     Abstract available


  47. CUI X, Li L, Yan G, Meng K, et al
    High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    BMC Cancer. 2015;15:244.
    PubMed     Text format     Abstract available


  48. CHEN J, Liu Z, Fang S, Fang R, et al
    Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.
    BMC Cancer. 2015;15:91.
    PubMed     Text format     Abstract available


  49. CAO WM, Gao Y, Yang HJ, Xie SN, et al
    Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer.
    BMC Cancer. 2016;16:64.
    PubMed     Text format     Abstract available


  50. LANE D, Matte I, Garde-Granger P, Laplante C, et al
    Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    BMC Cancer. 2015;15:492.
    PubMed     Text format     Abstract available


  51. CHEN S, Gou WF, Zhao S, Niu ZF, et al
    The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.
    BMC Cancer. 2015;15:471.
    PubMed     Text format     Abstract available


  52. ZHANG Y, Fan S, Xiang Y, Duan H, et al
    Comparison of the prognosis and recurrence of apparent early-stage ovarian tumors treated with laparoscopy and laparotomy: a meta-analysis of clinical studies.
    BMC Cancer. 2015;15:597.
    PubMed     Text format     Abstract available


  53. LI X, Pan Q, Wan X, Mao Y, et al
    Methylation-associated Has-miR-9 deregulation in paclitaxel- resistant epithelial ovarian carcinoma.
    BMC Cancer. 2015;15:509.
    PubMed     Text format     Abstract available


  54. HEMPEN A, Samartzis EP, Kamarachev J, Fink D, et al
    Acrokeratosis paraneoplastica in serous ovarian carcinoma: case report.
    BMC Cancer. 2015;15:507.
    PubMed     Text format     Abstract available


  55. HUANG R, Li X, Holm R, Trope CG, et al
    The expression of aldehyde dehydrogenase 1 (ALDH1) in ovarian carcinomas and its clinicopathological associations: a retrospective study.
    BMC Cancer. 2015;15:502.
    PubMed     Text format     Abstract available


  56. DU J, Li B, Fang Y, Liu Y, et al
    Overexpression of Class III beta-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer.
    BMC Cancer. 2015;15:536.
    PubMed     Text format     Abstract available


  57. TRENDOWSKI M, Christen TD, Acquafondata C, Fondy TP, et al
    Effects of cytochalasin congeners, microtubule-directed agents, and doxorubicin alone or in combination against human ovarian carcinoma cell lines in vitro.
    BMC Cancer. 2015;15:632.
    PubMed     Text format     Abstract available


  58. BURGHAUS S, Haberle L, Schrauder MG, Heusinger K, et al
    Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study.
    BMC Cancer. 2015;15:751.
    PubMed     Text format     Abstract available


  59. HO CM, Huang CJ, Huang SH, Chang SF, et al
    Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
    BMC Cancer. 2015;15:789.
    PubMed     Text format     Abstract available


  60. NISHIMURA T, Nakamura K, Yamashita S, Ikeda S, et al
    Effect of the molecular targeted drug, erlotinib, against endometrial cancer expressing high levels of epidermal growth factor receptor.
    BMC Cancer. 2015;15:957.
    PubMed     Text format     Abstract available


  61. MOTA A, Trivino JC, Rojo-Sebastian A, Martinez-Ramirez A, et al
    Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.
    BMC Cancer. 2015;15:940.
    PubMed     Text format     Abstract available


    December 2014
  62. TONE AA, McConechy MK, Yang W, Ding J, et al
    Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
    BMC Cancer. 2014;14:982.
    PubMed     Text format     Abstract available


  63. WANG Y, Herrstedt J, Havsteen H, DePoint Christensen R, et al
    A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    BMC Cancer. 2014;14:937.
    PubMed     Text format     Abstract available


    November 2014
  64. BRANDALIZE AP, Schuler-Faccini L, Hoffmann JS, Caleffi M, et al
    A DNA repair variant in POLQ (c.-1060A > G) is associated to hereditary breast cancer patients: a case-control study.
    BMC Cancer. 2014;14:850.
    PubMed     Text format     Abstract available


  65. HIRATA Y, Murai N, Yanaihara N, Saito M, et al
    MicroRNA-21 is a candidate driver gene for 17q23-25 amplification in ovarian clear cell carcinoma.
    BMC Cancer. 2014;14:799.
    PubMed     Text format     Abstract available


    September 2014
  66. SEONG MW, Cho SI, Kim KH, Chung IY, et al
    A multi-institutional study of the prevalence of BRCA1 and BRCA2 large genomic rearrangements in familial breast cancer patients.
    BMC Cancer. 2014;14:645.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: